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Abstract: Background: Sarcosine is an amino acid that is formed by methylation of glycine and is 
present in trace amounts in the body. Increased sarcosine concentrations in blood plasma and urine 
are manifested in sarcosinemia and in some other diseases such as prostate cancer. For this purpose, 
sarcosine detection using the nanomedicine approach was proposed. In this study, we have 
prepared superparamagnetic iron oxide nanoparticles (SPIONs) with different modified surface 
area. Nanoparticles (NPs) were modified by chitosan (CS), and sarcosine oxidase (SOX). SPIONs 
without any modification were taken as controls. Methods and Results: The obtained NPs were 
characterized by physicochemical methods. The size of the NPs determined by the dynamic light 
scattering method was as follows: SPIONs/Au/NPs (100–300 nm), SPIONs/Au/CS/NPs (300–700 
nm), and SPIONs/Au/CS/SOX/NPs (600–1500 nm). The amount of CS deposited on the NP surface 
was found to be 48 mg/mL for SPIONs/Au/CS/NPs and 39 mg/mL for SPIONs/Au/CS/SOX/NPs, 
and repeatability varied around 10%. Pseudo-peroxidase activity of NPs was verified using 
sarcosine, horseradish peroxidase (HRP) and 3,3′,5,5′-tetramethylbenzidine (TMB) as a substrate. 
For TMB, all NPs tested evinced substantial pseudo-peroxidase activity at 650 nm. The 
concentration of SPIONs/Au/CS/SOX/NPs in the reaction mixture was optimized to 0–40 mg/mL. 
Trinder reaction for sarcosine detection was set up at 510 nm at an optimal reaction temperature of 
37 °C and pH 8.0. The course of the reaction was linear for 150 min. The smallest amount of NPs 
that was able to detect sarcosine was 0.2 mg/well (200 µL of total volume) with the linear 
dependence y = 0.0011x − 0.0001 and the correlation coefficient r = 0.9992, relative standard deviation 
(RSD) 6.35%, limit of detection (LOD) 5 µM. The suggested method was further validated for 
artificial urine analysis (r = 0.99, RSD 21.35%, LOD 18 µM). The calculation between the detected 
and applied concentrations showed a high correlation coefficient (r = 0.99). NPs were tested for 
toxicity and no significant growth inhibition was observed in any model system (S. cerevisiae, S. 
aureus, E. coli). The hemolytic activity of the prepared NPs was similar to that of the phosphate 
buffered saline (PBS) control. The reaction system was further tested on real urine specimens. 
Conclusion: The proposed detection system allows the analysis of sarcosine at micromolar 
concentrations and to monitor changes in its levels as a potential prostate cancer marker. The whole 
system is suitable for low-cost miniaturization and point-of-care testing technology and diagnostic 
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systems. This system is simple, inexpensive, and convenient for screening tests and telemedicine 
applications. 
Keywords: superparamagnetic iron oxide nanoparticles; gold nanoparticles; biosensor; biomarker; 
Trinder reaction; personalized medicine 
 
1. Introduction 
1.1. Basal Metabolism 
Sarcosine (N-methylglycine; CH3NHCH2COOH), a key intermediate in one-carbon metabolism, 
[1] is enzymatically formed from dimethylglycine by dimethylglycine dehydrogenase (DMGHD; EC 
1.5.99.2) [2] and is generated from glycine by glycine-N-methyl transferase (GNMT; EC 2.1.1.20) [3]. 
Sarcosine is formed from dietary intake of choline and from the methionine metabolism, and is 
rapidly degraded [4] by the sarcosine dehydrogenase (SARDH; EC 1.5.99.1) [1] to glycine, which 
plays a substantial role in many physiological processes as a main metabolic source of components 
of living cells, such as glutathione, creatine, purines and serine [4]. SARDH is linked by electron-
transferring flavoprotein (ETF) to the respiratory redox chain [5]. Thus, sarcosine is a normal 
physiological metabolite and its concentration in blood serum of humans is reported to be 1.4 ± 0.6 
µM [4]. Increased levels of sarcosine have been found in various diseases (Figure 1). 
 
Figure 1. The physiological, pathophysiological role of sarcosine including its use as a food 
supplement or a drug. Sarcosine is detected in healthy people in very low concentrations and 
primarily is involved in the metabolism of creatine [4] and respiratory chain [5]. Several 
pathophysiological roles of sarcosine have been described, especially its elevated levels due to 
sarcosine dehydrogenase deficiency (sarcosinemia) [1] and also there are studies suggesting its 
importance in infarction, or aortic disorders [6]. A study suggested that plasma sarcosine could also 
be used as metabolic biomarker of HIV/AIDS infection [7]. Changes in sarcosine levels in urine are 
significantly associated with prostate tumors and may also represent specific targeting to tumor 
tissue. The addition of sarcosine was also used for the treatment of schizophrenia [8]. Sarcosine (N-
methylglycine) is an endogenous antagonist of glycine transporter-1, which potentiates glycine’s 
action on N-methyl-D-aspartate glycine site and can have beneficial effects on schizophrenia [9]. 
1.2. Sarcosinemia and Sarcosinuria 
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Mutations in the gene encoding sarcosine dehydrogenase (SARDH) are associated with an 
autosomal recessive disorder—sarcosinemia (OMIM 268900)—which is manifested by elevated levels 
of sarcosine in blood and urine. In the SARDH, four different mutations (P287L, V71F, R723X, R514X) 
were identified. In addition, uniparental disomy in the region of SARDH was found [1]. Sarcosinemia 
and sarcosinuria also occur in some patients with type II glutaric aciduria and with severe deficiency 
of folic acid [2]. 
1.3. Homocysteine Metabolism 
The metabolic pathway of sarcosine is linked to the metabolic pathway of betaine [10]. Large 
oral doses of betaine have proved effective in lowering plasma homocysteine in severe 
hyperhomocysteinaemia [11]. It was suggested that administration of precursors of methyl groups 
via N5-methyltetrahydrofolate (N5-MTHF), such as betaine or products of one-carbon metabolism 
(dimethylglycine, sarcosine, L-serine, or glycine), could be beneficial for patients suffering from 
homocystinuria. Betaine as a specific methyl donor is involved in the conversion of L-homocysteine 
to L-methionine [12]. After betaine administration, homocysteine level decreased and methionine 
level increased by providing an additional pathway for homocysteine transmethylation to 
methionine. During betaine addition, all patients experienced an increase in the ratio of plasma 
methionine/total homocysteine, regardless of estimated methionine intakes, compliance with 
methionine restriction or betaine [13]. 
1.4. Prostate Tumors 
Prostate cancer (PCa) is the second most common cancer and the fifth leading cause of death 
from cancer in men [14]. Despite the fact that the five-year survival rate for PCa patients with 
localized tumors exceeds 95%, patients with metastases have a total five-year survival less than 30% 
[15]. The gold standard for PCa diagnosis is the analysis of a prostate specific antigen (PSA) level in 
serum, but this biological marker is influenced by other factors besides progression or development 
of PCa [16]. PSA levels provide a valuable metric for PCa detection, however, the reliability of PSA 
as a surrogate biomarker for progression of this disease has recently been questioned [17]. Therefore, 
searching for other biomarkers associated with tumors has a key importance [15,18–24] and several 
of these have progressed into the clinical laboratory. In the glycine-N-methyl transferase (GNMT) 
gene, a 1289 C→T polymorphism was associated with cancer risk [25]. GNMT was down-regulated 
in most of the prostatic tumor specimens. Immunohistochemical staining displayed an abundant 
GNMT expression in normal prostatic and benign prostatic hyperplasia tissues compared with the 
PCa tissue [26]. It is known that epigenetic changes can be linked with carcinogenesis [27]. Altered 
methylation in some genes has been reported to be involved in the pathogenesis of PCa [28,29]. 
GNMT expression is decreased in PCa tissue and the loss of heterozygosity in the GNMT promoter 
region is associated with PCa [26]. Huang et al. [26] analyzed 4-bp insertion/deletion polymorphisms 
(INS/DEL) of GNMT and revealed that haplotype A (16GAs/DEL/C) carriers had significantly higher 
risk for PCa in comparison to haplotype C (10GAs/INS/T) individuals [26]. In addition, it was 
revealed that T allele of the rs9462856 single-nucleotide polymorphism (SNP) in the promoter region 
of the GNMT gene is overexpressed in patients suffering from PCa [30]. GNMT regulates S-
adenosylmethionine levels [31] and thus is a metabolic link between de novo synthesis of methyl 
groups and the availability of dietary methionine [26]. The GNMT enzyme influences DNA 
methylation by affecting de novo synthesis of methyl groups. [31] GNMT, by affecting DNA 
methylation, influences genetic stability [26]. Furthermore, research studies substantiated the role of 
sarcosine in PCa progression [3,32]. Sreekumar et al. [3] identified sarcosine as a potential mediator 
of PCa progression. Sarcosine levels were also increased in invasive PCa cell lines relative to benign 
prostate epithelial cells. This differential metabolite can be non-invasively detected in urine [3]. 
Metabolomic profiling of PCa progression identified substantially increased levels of sarcosine in 
metastatic PCa and moderate but significant elevation of the metabolite in PCa urine [32]. 
1.5. Nanoscale Materials in Cancer Diagnosis 
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The use of various nanostructures for different biological applications has been widely described 
[33–41]. A number of novel, highly sensitive diagnostic platforms [42] have recently been developed 
to measure biomolecules [42–46], with a great promise for early disease detection [42]. Systems based 
on gold nanoparticles (AuNPs) have been previously used for sensing amino acids [47–49]. 
Biosensing strategies based on magnetic nanoparticles (NPs), due to their unique properties such as 
financial affordability, high physical and chemical stability [42], displaying negligible background 
signal in biological specimens [50], and biocompatibility [39,42], have attracted great attention. 
Moreover, biological samples evince essentially no magnetic background, therefore, magnetic NPs 
can be used for biosensing applications, and highly sensitive measurements can be performed in 
visually obscured samples [42]. So far, numerous methods have been developed to sense 
biomolecules using magnetic labels [51,52]. In our previous study, superparamagnetic iron oxide 
nanoparticles (SPIONs) were used for an ultrasensitive specific biosensing system to detect sarcosine 
[53]. The great advantages of magnetic NPs in bioanalysis are their easy surface functionalization 
[53], a combination of the molecular-recognition-specific binding of analytes to their surface [54] and 
the specific elimination of undesirable (magnetically responsive) biomolecules adsorption from 
complex sample mixtures [55,56]. In this study, we used AuNPs combined with SPIONs, whose 
surface was modified with several different molecules. The aim of this work was to propose a highly 
sensitive and selective method for urinary sarcosine detection using enzyme modified SPIONs. 
The SPION-based detection method for sarcosine appears to be an appropriate alternative for 
the colorimetric method which is clinically routinely used for the determination of a variety of 
biomolecules. Both methods are based on the Trinder reaction [57–59]. In addition, in contrast to the 
colorimetric method [60] the nanotechnology approach has the advantage of easy manipulation and 
the use of inflow technologies such as microchips. 
2. Results 
2.1. Preparation and Physicochemical Characterization of Nanoconstructs 
We have prepared three types of differently modified SPIONs combined with AuNPs. The NP 
surface was modified either with citric acid, chitosan (CS), or CS and sarcosine oxidase (SOX) (see in 
Figure 2). The amount of SOX captured on the surface of the SPIONs showed 30–40% of the original 
enzymatic activity. 
 
Figure 2. Simplified scheme of prepared superparamagnetic iron oxide nanoparticles (SPIONs). (A) 
SPIONs/Au/NPs with the surface modified with citric acid; (B) SPIONs/Au/CS/NPs modified with 
chitosan (CS); (C) SPIONs modified with CS and sarcosine oxidase (SOX)—SPIONs/Au/CS/SOX/NPs. 
The nanoparticles (NPs) thus prepared were characterized in detail by physicochemical methods. See 
main text and Section 4 for experimental details. 
The obtained particles were characterized by physicochemical methods. Physicochemical 
characteristics of the prepared SPIONs are shown in Figure 3. The morphology of the used NPs was 
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determined by scanning electron microscopy (SEM). SEM images showed a homogeneous spherical 
NP population with a diameter of about 25 nm. The NP size obtained by the SEM analysis was 
described as follows: SPIONs/Au/NPs: 18–22 nm, SPIONs/Au/CS/NPs: 21–25 nm, and 
SPIONs/Au/CS/SOX/NPs: 24–28 nm. The size (aggregate size) distribution profile of the NPs was also 
measured by dynamic light scattering (DLS) method with the following values: SPION/Au/NPs—
10–100 nm (with a mean of 65 nm), SPIONs/Au/CS/NPs—250–450 nm (with a mean of 350 nm), and 
SPIONs/Au/CS/SOX/NPs—300–1200 nm (with a mean of 1085 nm). SPIONs/Au/NPs evinced a 
negative charge (−10 to −40 mV) (with a mean of −35 mV), whereas in SPIONs/Au/CS/NPs and 
SPIONs/Au/CS/SOX/NPs, the charge was positive—0 to 20 mV (with a mean of 12 mV) and 10 to 40 
mV (with a mean of 14 mV), respectively. The maxima of absorbance spectra observed for all the 
studied particles were found at about 530 nm. As shown in Figure 3, absorbance spectra of all three 
types of SPIONs have the usual course. SOX enzyme loaded onto the SPIONs is stable and 
transportable. 
 
Figure 3. Physicochemical characteristics of SPIONs used. Scanning electron microscopy (SEM) 
analysis, typical absorbance spectra, pseudo-peroxidase activity, size distribution and zeta potential 
of NPs: (A) SPIONs/Au/NPs; (B) SPIONs/Au/CS/NPs; (C) SPIONs/Au/CS/SOX/NPs (1 kU/L SOX). 
Top of the figure—SEM photographs of prepared nanoparticles (NPs)—an overview photo (on the 
left) and close-up of a photo (on the right) of SPIONs. Middle of the figure—typical absorbance 
spectra and pseudo-peroxidase activity. Spectrophotometric measurements were carried out in 50 
mM phosphate buffer, pH 8.0 in a UV cuvette filled with 100 µL of NPs and 1000 µL of 50 mM 
phosphate buffer. The small graphs above the graphs of absorbance vs. wavelength represent pseudo-
peroxidase activity of the respective SPION particles after 5 min reaction (3,3′,5,5′-
tetramethylbenzidine (TMB) reduction). Bottom of the figure—distribution diagrams of the size and 
graphs of the dependence of the signal intensity on zeta potential of SPIONs. The amount of SPIONs 
used was 40 mg/mL. Other experimental details are in Section 4. 
2.2. Pseudo-Peroxidase Activity of the Gold SPIONs 
Pseudo-peroxidase activity of all three prepared types of SPIONs is demonstrated in Figure 4. 
Figure 4A shows images of characteristic appearance of individual types of SPIONs used depending 
on their amount. Further, a typical color changed from colorless to shades of blue (Figure 4B). The 
time course with change of absorbance (Figure 4C) of pseudo-peroxidase reaction with 
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SPIONs/Au/NPs can be seen. In addition, the signal intensity of SPIONs/Au/NPs in dependence on 
the amount of NPs (Figure 4D), can also be observed. 
 
Figure 4. Pseudo-peroxidase activity of SPIONs/Au/NPs, SPIONs/Au/CS/NPs, 
SPIONs/Au/CS/SOX/NPs. Photographs (camera Canon PowerShot SX610 HS, 20.2 Mpx CMOS 
sensor, ultra-wide-angle lens with 18× superzoom) showing (A) a typical appearance of individual 
used types of SPIONs in a range of concentrations from 0 to 40 mg/mL in 50 mM phosphate buffer 
(pH 8.0) and (B) a typical color course of pseudo-peroxidase reaction with SPIONs/Au/NPs in a range 
of concentrations from 0 to 40 mg/mL; representative image; (C) time course of pseudo-peroxidase 
reaction (0 to 30 min) for SPIONs/Au/NPs in a range of concentrations from 0 to 10 mg/mL; 
SPIONs/Au/CS/NPs and SPIONs/Au/CS/SOX/NPs (0–40 mg/mL); (D) Signal intensity of 
SPIONs/Au/NPs, SPIONs/Au/CS/NPs and SPIONs/Au/CS/SOX/NPs in dependence on pseudo-
peroxidase reaction signal in a range of concentrations from 0 to 40 mg/mL. Composition of reaction 
mixture for the measurement of pseudo-peroxidase activity was as follows: 5 mM TMB, hydrogen 
peroxide 30%, 0.5 M acetate buffer pH 4. The measurement was carried out in the Brand plate after 
washing with 18 MΩ water, at 650 nm in 1 min reading interval, each value being the average of five 
repeated measurements. Other experimental details are in Section 4. 
2.3. Characterization of SPIONs Using Ninhydrin Assay 
For detection of CS adsorbed to NP surface, the ninhydrin assay was used. The scheme in Figure 
5A demonstrates the principle of ninhydrin reaction with CS to characterize CS NPs. The calibration 
curve of CS in a ninhydrin assay (Figure 5A) was also constructed in independent repetitions for five 
days (Figure 5B). The color intensity of the ninhydrin complex formed was spectrophotometrically 
evaluated as a measure of depolymerized CS activity. A typical absorption spectrum of ninhydrin 
complex in the case of CS alone is shown in Figure 5C. The absorption spectra of individual types of 
prepared SPIONs are depicted in Figure 5D–F). Relative absorbance (RA ninhydrin factor) of each 
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prepared CS-coated SPIONs solution was calculated as follows: RA = absorbance of 100 µg/mL CS 
solution/absorbance of NPs solution (Figure 5G). The amount of CS on SPIONs/Au/CS/NPs and 
SPIONs/Au/CS/SOX/NPs surfaces was found to be 48 mg/mL and 39 mg/mL respectively, and 
repeatability varied around 10%. 
 
Figure 5. Ninhydrin assay for evaluation of different modifications of SPIONs. (A) Calibration curve 
of chitosan (CS) in a ninhydrin assay. The calibration curve was made from five independent repeats 
with 95% confidence band. In the inset, the variability of the individual values with the confidence 
band as a variability index; (B) the independent repetition of the calibration curve shown in (A) with 
a slope. The left vertical axis of the graph measures the slope of the straight lines of the repetitions 
from five independent days (red-white striped columns). The right vertical axis measures the RSD 
error of calculation of the backward concentration (green triangles) and the average error from the 
standard deviation of individual measurements of the repeat point variability (blue diamonds). It was 
calculated by fitting the values into the calibration curve. A typical absorption spectrum of ninhydrin 
complex in two independent preparations (blue and red line), with a photographic illustration (20.2 
Mpx): (C) CS (100 µg/mL); (D) SPIONs/Au/NPs; (E) SPIONs/Au/CS/NPs; (F) 
SPIONs/Au/CS/SOX/NPs) (G) RA ninhydrin factor of the prepared SPIONs in two independent 
preparations. Measurements were performed in a 96-well microplate as a scan. Blank was a ninhydrin 
reagent. Sample was prepared as following: 10 mL of nanoparticles (NPs) was incubated with 
ninhydrin (20 mg/mL) reagent for 30 min at 100 °C. RA ninhydrin factor was calculated as the ratio 
of 100 µg/mL CS signal/CS signal of NPs. Error bars were calculated from 5 independent 
measurements. 
2.4. Characterization of SPIONs for Sarcosine Detection—SOX Activity of SPIONs/Au/CS/SOX/NPs 
SOX activity of SPIONs/Au/CS/SOX/NPs was performed using 4-aminoantipyrine (4-AAP) 
(Figure 6). The absorbance spectra were characteristic as can be seen in Figure 6A. Figure 6B illustrates 
the dependence of absorbance on the reaction time course. We tested the effect of the reaction 
temperature and pH (Figure 6C,D) for determining the optimal conditions for SOX activity and then 
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the final conditions for the preparation of urine specimens and for the detection of sarcosine. Figure 
6E,F represent the dependence of signal and absorbance, respectively, on various concentrations of 
sarcosine. Even at lower concentrations of sarcosine (to 100 µM), the reaction was sensitive leading 
to the emergence of the signal (Figure 6E), whereas at higher concentrations of sarcosine (to 0.5 mM), 
the absorbance increased linearly (Figure 6F). The absorbance linear curve showed a good 
reproducibility. The course of the calibration curve in artificial urine is shown in Figure 6G. Figure 
6H illustrates the comparison between applied and calculated concentration of sarcosine from the 
calibration curve. 
 
Figure 6. Determination of SOX activity of SPIONs/Au/CS/SOX/NPs using 4-AAP. 4-AAP reaction 
dependence of time reaction course. (A) Typical absorbance spectra (350–800 nm), time measurements 
, the first time is zero and measurements were repeated after 3 min up to 60 min and can be seen how 
the curve rises (i.e., last green line is measurement after 60 min; the penultimate red is measurement 
after 57 min, and so forth); (B) 4-AAP reaction dependence of the signal at 500 nm on reaction time of 
the main signal; (C) 4-AAP reaction dependence on the temperature (25, 30, 35, 37, 38, 39, 40 °C) of 
the enzyme reaction; (D) 4-AAP reaction dependence on pH (6.0, 6.5, 7.0, 7.5, 8.0) effect of the enzyme 
reaction. Dependence of signal intensity: (E) on high sarcosine concentration (0–0.5 mM); and (F) low 
concentrations of sarcosine (0–100 µM); (G) sarcosine in artificial urine (0–100 µM); (H) correlation 
between the applied and calculated concentration of sarcosine (0–10 µM). Error bars were calculated 
from 5 independent measurements. Other details are provided in Section 4. 
SOX assay with various amounts of SPIONs/Au/CS/SOX/NPs (0.2–2.0 mg/well) is presented in 
Figure 7A–L. For each of the six tested concentrations, a good calibration curve was obtained. The 
obtained dependencies were linear (r = 0.98–0.99), with RSD in the range of 5–15% depending on the 
amount of NPs added. The detection system was also very reproducible in the presence of a very 
small amount of modified NPs. 
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Figure 7. SOX activity of SPIONs/Au/CS/SOX/NPs depending on the concentration of the NPs. 
Various amounts of SPIONs/Au/CS/SOX/NPs (0.2, 0.4; 0.8; 1.2; 1.6; 2.0 mg/well) were pipetted into 
the microtiter plate. (A) Absorbance scan on various concentrations of sarcosine; (B) dependence 
signal TMB on various concentrations of sarcosine; 2.0 mg of nanoparticles (NPs) per well; (C) 
absorbance scan on various concentrations of sarcosine; (D) dependence signal TMB on various 
concentration of sarcosine; 1.6 mg of NPs per well; (E) absorbance scan on various concentrations of 
sarcosine; (F) dependence signal TMB on various concentrations of sarcosine; 1.2 mg of NPs per well; 
(G) absorbance scan on various concentrations of sarcosine; (H) dependence signal TMB on various 
concentrations of sarcosine; 0.8 mg of NPs per well; (I) absorbance scan on various concentrations of 
sarcosine; (J) dependence signal TMB on various concentrations of sarcosine; 0.4 mg of NPs per well; 
(K) absorbance scan on various concentrations of sarcosine; (L) dependence signal TMB on various 
concentrations of sarcosine; 0.2 mg of NPs per well. Spectrophotometric measurements of SOX 
activity were performed at temperature of 23 °C for 30 min after the addition of sarcosine. They were 
aspirated to dryness, then 125 µL of colored substrates (4-AAP, phenol, triton X-100, pH 8 phosphate) 
and 25 µL of various sarcosine concentrations in water (0, 0.4, 0.8, 1.6, 3.1, 25, 50, 100 µg/mL) were 
added. All measurements were performed in five replicates in the range of 350–700 nm for scans and 
510 nm for concentration dependencies. For graphs A, C, E, G, I and K each line represents one 
concentration of nanoparticles (blue is 2.0 mg / well, green is 1.6 mg / well, purple is 1.2 mg / well, 
light blue is 0.8 mg / well, etc.) For other details see Section 4. K 
2.5. Assessing Toxicity of SPIONs 
Toxicity of SPIONs was tested on both eukaryotic model organism S. cerevisiae, and 
microorganisms—Gram negative (E. coli) and Gram positive (S. aureus) species of bacteria (Figure 8). 
For toxicity determination, the half maximal inhibitory concentration (IC50) was calculated. IC50 for 
SPIONs/Au/NPs ranged for each biological model within the range of values from 5.1 to 7.6 mg/mL 
(Figure 8A–C). However, SPIONs modified with both CS and SOX were compared to non-modified 
SPIONs far less toxic to the yeast and bacterial models used. As shown in Figure 8A, a modification 
with CS and SOX markedly decreased (almost seven times) toxicity in S. cerevisiae, compared to 
control SPIONs (without any modification), whereas in both bacteria species, the highest value of 
IC50 was found in CS-stabilized SPIONs. Toxicity of SPIONs/Au/CS/NPs compared to 
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SPIONs/Au/NPs in E. coli and S. aureus was found to be 3.1 and 3.7 times lower, respectively (Figure 
8B,C). Thus, CS and SOX modification prolonged inhibition of biological processes. 
 
Figure 8. Toxicity study of individual investigated types of SPIONs performed in (A) eukaryotic cells 
S. cerevisiae; and prokaryotic cells (B) E. coli; (C) S. aureus. 100 µL of the microorganism culture and 50 
µL of nanoparticles (NPs) were pipetted into the 96-microwell plate and then 50 µL of pure medium 
added. The cultures were grown for 16 h at 37 °C. Time scans of optical density (600 nm) were 
measured at regular intervals (15 min) and average five times measurement. Other experimental 
details are in Section 4. 
2.6. Analysis of SPIONs Hemolytic Properties In Vitro 
Hemolytic activity of each type of SPION was tested at various concentrations in the range 2.5–
40 mg/mL (Figure 9A), with water and PBS as a positive and negative control, respectively. The in 
vitro hemolysis assay was performed on human erythrocytes and calculated based on the above-
mentioned formula (see Section 4). The SPION respective of absorbance spectra curves (Figure 9B) 
and graph of hemolytic activity (Figure 9C) showed a very low toxicity to red blood cells. 
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Figure 9. Determination of hemolytic activity of prepared nanoparticles (NPs). (A) Photographs of 
each variant (centrifugation 2000× g, 5 min to a completely clear solution). Tested variants: water 
(positive control), 1× PBS, pH 7.0 (negative control), SPION/Au/NPs, SPION/Au/CS/NPs, 
SPION/Au/CS/SOX/NPs (40, 20, 10, 5, 2.5 mg/mL). (B) Supernatant was spectrophotometrically 
analyzed, the absorbance spectra were obtained and the results were evaluated at 570 nm (light blue 
line is a positive control, dark blue line is a negative control, and violet, green and red lines represent 
40, 20, 10, 5, and 2.5 mg/mL of NPs, respectively. (C) Relative comparison of hemolytic activity of 
tested NPs, 100% of water is a positive control. Experiment was carried out in four replications. Blood 
parameters were: RBC (red blood cells) 5.16 × 1012 L; HBG (hemoglobin) 161 g/L; MCV (mean 
corpuscular volume) 83.6 fL. Error bars were calculated from 5 independent measurements. For other 
details see Section 4. 
2.7. Application of SPIONs for Urine Sample Analysis 
Based on SOX assay and artificial urine analysis, we applied the obtained findings to real urine 
samples, and subsequently, sampling with sarcosine secreted over time (Figure 10B). Trinder reaction 
with 4-AAP at various concentrations applied into urine sarcosine resulted in the formation of 
sarcosine concentration-dependent colored product as depicted in Figure 10A. Figure 10B illustrates 
the content of sarcosine converted to mmol of creatinine level in patient samples as well as healthy 
controls. Changes in urine sarcosine levels after administration in time showed the highest value after 
480 min. Figure 10B shows that the sarcosine content ranged from 1 to 6 µM/creatinine mM (mean 
3.6 µM/ creatinine mM) in healthy volunteers, whereas, in PCa patients ranged around 64–140 µM/ 
creatinine mM (with a mean of 96.4 µM/ creatinine mM). Thus, the content of sarcosine in the urine 
of PCa patients is about 27 times higher than in healthy people. Furthermore, our previous study [61] 
revealed that the level of urinary sarcosine in healthy patients is very low, and its level in patients 
suffering from PCa is several times higher than that of cured patients. 
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Figure 10. Application of nanoparticles (NPs) for urine sample analysis. (A) A typical course of SOX 
color reaction at various applied sarcosine concentrations in urine specimen; (B) Time changes in 
urine sarcosine levels after peroral application (1.5 g). The small bar graph: Sarcosine levels in urine 
specimens from donors with PCa (P1, P2, P3, P4, P5) and donors without PCa (H1, H2, H3, H4, H5). 
Error bars were calculated from 5 independent measurements. The amount of sarcosine was 
converted to creatinine (more details are given in Section 4). 
3. Discussion 
3.1. Preparation and Physicochemical Characterization of Nanoconstructs 
NPs are unique tools for very efficient and effective separation and for monitoring biological 
processes. Nanomedical usability of such NPs dramatically increases due to their potential in 
enhancing extremely sensitive and selective diagnostics of serious diseases including cancer. The 
SPIONs (γ-Fe2O3 and Fe3O4) are multi-purpose nanoscaled materials that have been used in various 
applications [62–64]. SPIONs consist of a solid core made up of iron oxides (magnetite, Fe3O4 and/or 
maghemite, Fe2O3) mostly coated with biocompatible polymers [65]. They can be easily 
functionalized to provide binding sites for various types of molecules [53]. The coating agent plays a 
double role: it protects NPs from oxidation and enhances their stability when dispersed in aqueous 
media [65]. SPIONs were used in our previous study, where we introduced an ultrasensitive specific 
biosensing system for detection of sarcosine as a potential biomarker of PCa [53]. In this study, we 
used them in combination with AuNPs and modified them with citric acid, and we used CS and SOX 
as surface coatings (Figure 2). CS, due to its excellent film-forming ability, high permeability, ease of 
chemical modification, mechanical strength, non-toxicity, and low cost, is considered to be one of the 
most-used biopolymers for immobilization of biomolecules. In addition, −NH2 groups of CS provide 
the hydrophilic environment for the biomolecules [66]. SOX has been recently used for improvement 
of amperometric biosensor for detection of creatinine [67] and sarcosine [68]. Narwal et al. [68] 
described the construction of an amperometric sarcosine biosensor based on covalent immobilization 
of SOX onto the nanocomposite of carboxylated multi-walled carbon nanotubes/CS and copper NPs 
(CS/CuNPs/MWCNT) modified gold electrode with better analytic performance. AuNPs have been 
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also recently used for development of sensing system for sarcosine detection [69,70]. The size of 
prepared SPIONs (Figure 3) obtained by SEM analysis (18–28 nm) showed relatively narrow size 
distributions which are in accordance with the studies of Hirsch et al. [71] that reported the size of 
28.3 ± 2.1 nm in polyvinyl alcohol (PVA)-coated SPIONs (PVA-SPIONs), and of Park et al. [72] that 
measured the size ranging from 22.4 to 25.1 nm in polymer-coated SPIONs. Mardinoglu and Cregg 
et al. [73] used three different sizes of SPIONs coated with oleic acid with diameters 6.6, 11.6, and 
17.8 nm, and Kapri et al. [74] synthesized SPIONs with size in the range of 10.6–37.8 nm (10.6, 20.0 
and 37.8 nm). Herve et al. [75] reported the size of PEG[poly(ethylene glycol]ylated SPIONs to be 82.4 
± 7.9 nm. Moreover, the size of particles grew with the degree of surface functionalization—with each 
coating the size increased (18–22 vs. 21–25, and 24–28 nm for SPIONs/Au/NPs, SPIONs/Au/CS/NPs, 
and SPIONs/Au/CS/SOX/NPs, respectively). This result is consistent with the observation of Herve 
et al. [75] that found the average hydrodynamic size of PEGylated NPs to be higher than those of the 
initial and silanized SPIONs. The increase in hydrodynamic size of NPs was consistent with PEG 
coating [75]. For comparison, the NPs PEGylated using covalent surface binding by Xie et al. [76] 
exhibited a size distribution with a narrow maximum at 70 nm as measured by DLS. Zeta potential 
measurement was also performed to determine the potential stability and polarity of the NPs [65]. 
The physical stability is one of the most critical requirements for a NP system [77]. The zeta potential 
value is a characteristic that points to the storage stability of colloidal dispersions [78]. A high zeta 
potential (+ or −) value reflects the electrostatic interaction within a NP system and is a feature of the 
dispersion stability of SPIONs [79]. In the present study, the zeta (ζ) potential of SPION/Au/NPs, 
SPIONs/Au/CS/NPs, and SPIONs/Au/CS/SOX/NPs was found to be −35, 12 and 14 mV, respectively 
(Figure 3A–C). After the SPIONs/Au/NPs synthesis, the negative charge typical for AuNPs [80–82] 
remained (zeta potential from −10 to −40 mV). In the remaining two types of NPs, the charge was 
positive: for SPIONs/Au/CS/NPs zeta potential ranged from 0 to 20 mV, and for 
SPIONs/Au/CS/SOX/NPs from 10 to 40 mV, which may be attributed to positive charge on surface of 
NPs due to the presence of functional groups of surface coating, such as –NH2 group of CS. De Palma 
et al. [83] measured negative values of zeta potential at pH values over the range 3–9 in magnetic 
NPs with amino endgroups, in contrast to those with carboxyl groups. The amino groups exhibit an 
isoelectric point (pI) of 10.4, which provides a continuous positive charge over the entire lower pH 
range due to the presence of NH3+ groups. The differences in zeta potential are affected by many 
factors, especially by a type of surface coating and pH of the solution [84]. However, the 
characterization of the different charged SPIONs of one type (neutral, positive, negative PVA-
SPIONs) clearly showed that only the zeta potential varies between each NP type, whereas the 
particle sizes remain comparable [71]. As shown in Figure 3, in the presence of SOX, the character of 
the absorbance spectrum changed. 
3.2. Pseudo-Peroxidase Activity of the Gold SPIONs 
Due to their large surface-to-volume ratio, nanomaterials are attractive to be used as high-
efficiency catalysts [85], and some of them have been found to have enzyme-like activity. To date, a 
variety of NPs, especially those formed from noble metals, have been determined to possess oxidase-
, peroxidase-, catalase-, and/or superoxide dismutase-like activity [86]. Various research manuscripts 
on nanomaterials deal with their peroxidase-[87–95] or oxidase-like activity [96]. Pseudo-peroxidase 
activity of the AuNPs is very intensively investigated [97,98]. AuNPs are known to possess intrinsic 
biological peroxidase-like activity [90,99] that makes them appropriate for biosensor development 
[99]. In addition, Xu et al. [100] found that gold NPs bound on microgel particles could enhance the 
performance of horseradish peroxidase. In addition, AuNPs are observed to enhance the activities of 
glucose oxidase [101]. In conclusion, considering the high peroxidase-like activity, good 
cytocompatibility and ease of preparation, CS-AuNPs have a wide range of potential applications in 
biocatalysis and bioassays [97]. Gao et al. [88] found that Fe3O4 magnetic NPs possessed intrinsic 
enzyme mimetic activity similar to that found in natural peroxidases, though Fe3O4 magnetic NPs are 
thought to be biologically and chemically inert and they were subsequently used as peroxidase 
mimetics for H2O2 and glucose detection [93]. The peroxidase-like activity of Fe3O4 magnetic NPs has 
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been also recently used for the development of immunochromatographic strip (Nanozyme-strip) for 
the rapid and sensitive detection of the Ebola virus glycoprotein [102]. Fang et al. [103] used 
Fe3O4/reduced graphene oxide (rGO) nanocomposites as the peroxidase mimic to prepare the 
modified glassy carbon electrode for electrochemical sensing of H2O2. In our study, we investigated 
the catalytic properties of the fabricated gold SPIONs (Figure 4). Functionalized AuNPs are the most 
prevalent gold surface biomarker detection platform [104]. The initial experimental characterization 
of AuNPs has been carried out in our previous study [105]. Furthermore, we have published 
physicochemical characterization of gold magnetic NPs (AuNPs) [106]. We are very intensively 
engaged in the pseudo-peroxidase activity of AuNPs. In this work, the peroxidase-like activity was 
evaluated in the catalytic oxidation of peroxidase substrate 3,3′,5,5′-tetramethylbenzidine (TMB), 
with the addition of H2O2 and acetate buffer. The proposed procedure was used to maximize the 
amplification of the resulting colored product (TMB). TMB substrate show a very good course of 
reaction depending on the type of AuNPs used. The TMB cation free radical is a one-electron 
oxidation product, which is formed by exposing TMB to peroxidase and H2O2. In addition, the TMB 
cation free radical is responsible for the blue color formed during the TMB oxidation [107]. The 
catalytic reaction was detected by monitoring absorbance change of oxidation products of TMB at 
650 nm, similarly as reported in the study of Lv and Weng [108]. This work observed the peroxidase 
activity of hemin-graphene-gold (H-RGO-Au) ternary composite, leading to TMB oxidation at 652 
nm. The same maximum absorbance was reported also by Marquez et al. [107] The catalytic activity 
of SPIONs was illustrated by catalyzing the oxidation reaction of TMB accompanied with a color 
change. As can be seen in Figure 4B, the color change is dependent on the concentration of TMB. The 
ability of SPIONs to oxidize TMB substrate accompanied by color reaction is shown in Figure 4B. 
3.3. Characterization of SPIONs Using Ninhydrin Assay 
We used ninhydrin assay to monitor CS properties in the presence of sodium tripolyphosphate 
(TPP), which has been used in our previous study [109], in which we have investigated the effects of 
some factors (the reaction temperature, reaction time and the ninhydrin concentration) on the CS-
ninhydrin reaction to optimize the specificity and sensitivity. TPP stabilizes CS crosslinked structure 
and provides NP formation [109]. Ninhydrin assay was used for quantitative determination of CS by 
ninhydrin [110]. CSs are linear binary heteropolysaccharides composed of (1–>4)-linked 2-acetamido-
2-deoxy-β-D-glucopyranose (GlcNAc) and 2-amino-2-deoxy-β-D-glucopyranose (GlcN) [110]. The 
relaxed structure of CS has an accessible amino group for ninhydrin reaction (Figure 5A). When TPP 
is added, the structure of CS is strongly crosslinked leading to the NP formation. The number of 
accessible amino groups decreases proportionally with the level of crosslinking and the structure of 
NPs formed. This behavior results in less accessible amino groups which causes lower absorbance 
signal of ninhydrin [110,111]. The color intensity of the ninhydrin complex was 
spectrophotometrically evaluated as a degree of depolymerized CS activity. The absorption spectra 
of ninhydrin complex for CS along with all three types of prepared SPIONs were characteristic 
(Figure 5C–F). According to a previous study, only the GlcN units of CSs are responsible for creating 
colored products with ninhydrin [110]. Firstly, the absorbance of ninhydrin was investigated in the 
presence of TPP. From Figure 5A, B is obvious that the equal signal intensity for all applied 
concentrations is comparable to ninhydrin signal intensity at A572. Further results are interleaved by 
the signal intensity of the CS alone (A572). Figure 5B shows the good repeatability of the directives of 
the lines of Figure 5A in individual days. Figure 5C demonstrates a decrease in the signal of the 
formed NPs in CS (Figure 5D–F). The very good reproducibility (Figure 5G) can be further assessed 
by looking at the bar graph of the RA factor (the result is always in two repeats) calculated according 
to the Equation 1 illustrated in Section 4. 
3.4. Characterization of SPIONs for Sarcosine Detection—SOX Activity of SPIONs/Au/CS/SOX/NPs 
Sarcosine was found to be significantly higher in urine sediments and supernatants derived from 
biopsy positive PCa patients as compared to biopsy negative controls [3]. Sarcosine was also reported 
to be a differential metabolite that is greatly increased during PCa progression [112]. In 2015, more 
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than one million new prostate cancer patients were diagnosed [113]. Some studies have also reported 
measurement of sarcosine level in blood serum for diagnosis and medical management of PCa [68]. 
Sarcosine oxidase (SOX, EC 1.5.3.1) is a monomeric or heterotetrameric flavoprotein that catalyzes 
the oxidative demethylation of sarcosine (N-methylglycine) to yield glycine, formaldehyde, and 
hydrogen peroxide [114]. Monomeric SOX is often used with creatininase, creatinase, and 
horseradish peroxidase in enzymatic assays of creatinine and creatine in clinical settings [115]. The 
catalytic activity of the ferromagnetic NPs is dependent on pH, temperature and H2O2 concentration 
[116]. Directed evolution was used to expand the substrate specificity and functionality of SOX by 
using screening assay based on the 4-aminoantipyrine (4-AAP) peroxidase system (Figure 6). When 
used in the presence of phenol, 4-aminoantipyrine can be utilized to measure the peroxidase activity. 
Hydrogen peroxide is coupled with 4-aminoantipyrine and phenol in the presence of peroxidase to 
yield a chromogen (quinoneimine dye) with a maximum absorbance of at about 500 nm. This allows 
4-aminoantipyrine to be used as a reagent in the determination of chemicals, in particular those in 
which the method of detection is coupled through peroxidase and other coupling enzymes. SOX 
assay using 4-APP reaction showed characteristic and reproducible absorbance spectra (Figure 6A). 
Figure 6B shows the slow linear course of the enzymatic reaction over time. We measured the 
peroxidase-like activity (510 nm) SPIONs/Au/CS/SOX/NPs while varying the pH from 6 to 8 at 
intervals of 0.5 and the temperature ranging from 25 to 40 °C as illustrated in Figure 6C,D, 
respectively. As evidenced by bar graphs (Figure 6C,D), the optimal pH and temperature were pH 
8.0 and 37 °C, which are in good agreement to SOX activity of the enzyme solution used by Nishiya 
et al. [115] Thus, we adopted pH 8.0 and 37 °C as standard conditions for subsequent analysis of 
SPIONs/Au/CS/SOX/NPs activity. Even at lower concentrations of sarcosine (to 100 µM), the reaction 
was sensitive leading to the emergence of the signal (Figure 6E), whereas at higher concentrations of 
sarcosine (to 0.5 mM), the absorbance increased linearly with a good reproducibility (Figure 6F). The 
course of the calibration curve in artificial urine (Figure 6G) demonstrated that the calibration curve 
in urine was linear with very good reproducibility. The above procedure can be used for real urine 
sample analysis. Moreover, a high correlation value (r2 = 0.99) between the measured sarcosine value 
and the determined sarcosine concentration from the regression equation was obtained. It also shows 
the excellent reproducibility and applicability of the method for the real sample analysis (Figure 6H). 
Testing SOX activity with varying amounts of SPIONs/Au/CS/SOX/NPs (Figure 7A–L) has clearly 
shown that the proposed assay is also applicable for analyzing small amounts of particles, such as 0.2 
mg/well (200 µL of total volume) (Figure 7L). This amount of NPs was able to detect sarcosine with 
the linear dependence y = 0.0011x - 0.0001 and the correlation coefficient r = 0.9992, RSD 6.35%, LOD 
5 µM (Table 1). The suggested method was also validated for an artificial urine analysis (r = 0.9912, 
RSD 21.35%, LOD = 18 µM). The analytical parameters of both validations (in water and in artificial 
urine) are summarized in the Table 1. 
Table 1. Analytical description of the determination of sarcosine in matrices. 
Substance 
Regresion 
Equation 
Linear Dynamic Range 
(µM) 
Correlation Coefficient 
(r) 
LOD 
(µM) 
LOQ 
(µM) 
RSD 
(%) 
Sarcosine #  y = 0.0011x − 0.0001 17–100 0.9992 5 17 6.35 
Sarcosine * y = 0.0010x + 0.0006 59–100 0.9912 18 59 21.35 
# (in water); * (in artifical urine); five repetitions; limit of detection (LOD) and limit of quantification 
(LOQ) were calculated by ISO (International Organization for Standardization) method. 
3.5. Assessing Toxicity of SPIONs 
The value of IC50 for SPIONs/Au/NPs in a S. cerevisiae eukaryotic model organism was found to 
be 5.3 mg/mL (Figure 8A). For comparison, AuNP-induced cytotoxicity in human tumor cells 
expressed as IC50 was higher than 15 µg/mL [117], i.e., more than 350 times lower than in our study. 
Smith et al. [118] found that yeast cell growth, assessed as cell yield, was unaffected by exposing 
intact cells to as much as 22 µM of the 0.8 nm AuNPs functionalized with positively charged N,N,N 
trimethylammoniumethanethiol (TMAT), corresponding to the 100 µg/mL dose. Moreover, 
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modification with CS and SOX led to an increase in IC50 value for yeast cells to 17.9 and 36.1 mg/mL, 
respectively (Figure 8B,C). CS is considered to be non-toxic for eukaryotic cells [119,120]. Pokharkar 
et al. [119] reported that CS-AuNPs did not cause any signs of intoxication after dosing to rats: the 
LD50 value was found to be greater than 2 mg/g. In addition, CSs (having different Mw and DD; <5 
kDa, 65.4% DD; 5–10 kDa, 55.3% DD; and >10 kDa, 55.3% DD) were found to display little cytotoxicity 
against CCRF-CEM (human lymphoblastic leukemia) and L132 (human embryonic lung cells) (IC50 
>1 mg/mL) [121]. Moreover, CS was reported to possess hepatoprotective effects [122]. The increase 
in IC50 after SOX modification can be related to the fact that SOX is a protein involved in cell 
metabolism, and creates a protein corona that prevents from toxic effects. The IC50 values in non-
modified AuNPs for prokaryotic model organisms E. coli and S. aureus were found to be 7.6 and 5.1 
mg/mL, respectively, and similarly as for yeast, SPIONs modified with both CS and SOX were far 
less toxic (Figure 8B,C). Interestingly, in contrast to S. cerevisiae, CS caused a greater increase in IC50 
value than SOX, because CS is widely known for its toxic effect to microorganisms either alone or 
blended with other natural polymers [123], and it exhibits toxicity to Gram-negative [124–126] as well 
as Gram-positive bacteria [124,125,127]. In our study, however, SPIONs/Au/NPs exhibited the most 
pronounced antibacterial activity against both test microorganisms, compared to SPIONs/Au/CS. IC50 
in E. coli and S. aureus was found to be 3.1 and 3.7 times lower, respectively, for CS-modified SPIONs 
than for those without functionalization (Figure 8B,C). Thus, CS modification of gold SPIONs 
surprisingly prolonged inhibition of biological processes. 
3.6. Analysis of SPIONs Hemolytic Properties In Vitro 
Hemolysis is defined as the damage caused to red blood cells (RBCs), which results in the release 
of the iron-containing protein hemoglobin into plasma [128]. The small size and unique 
physicochemical properties of NPs may cause their interactions with erythrocytes to differ from those 
observed for conventional pharmaceuticals and may also cause interference with standardized in 
vitro tests. Separating true hemolytic responses from the false-positive or false-negative results 
caused by particle interference is important for correct interpretation of these tests [129]. Hemolysis 
assay was also used to assess the overall toxicity of prepared NPs. The hemocompatibility of the 
SPIONs was assessed by in vitro hemolysis assay (Figure 9A). The impact of NPs on human red blood 
cells lysis was carried out spectrophotometrically recording the absorbance of hemoglobin at 570 nm 
(Figure 9B). Each of SPIONs prepared evinced a very low hemolytic activity as can be seen in Figure 
9B,C. The level of hemolytic activity declined with the degree of modification and it was found to be 
5, 3 and 1% compared to positive control (deionized water) for SPION/Au/NPs, SPION/Au/CS/NPs, 
and SPION/Au/CS/SOX/NPs, respectively (Figure 9C). Thus, the highest hemolytic activity showed 
pristine (non-modified) gold SPIONs, whereas due to the formation of the protein corona by the SOX 
enzyme SPION/Au/CS/SOX/NPs exhibited five times lower toxicity to human erythrocytes. This 
finding corresponds very well to the IC50 testing of the NPs toxicity in eukaryotic model (Figure 8A). 
Our results are in accordance with results of another previous study, in which has been suggested 
that NP coating can reduce hemolytic toxicity of NPs [130]. This result is also in agreement with 
results of our previous study, in which the hemolytic activity of unmodified CS was observed to be 
67%, and after CS NPs formation, hemolytic activity decreased by 30% [109]. Moreover, our findings 
confirm a high hemocompatibility of CS reported by Richardson et al. [121] that found that hemolysis 
was not observed (<10%) over 1 h and 5 h with CSs of <5 kDa, 5–10 kDa and >10 kDa at concentrations 
of up to 5 mg/mL. 
3.7. Application of SPIONs for Sarcosine Analysis in Urine Samples 
A number of methods have been developed for the detection of sarcosine [61,112,131,132]. 
Sarcosine levels in plasma of PCa patients were measured by fluorometric assay [112]. The content 
of sarcosine in PCa tissue samples was analyzed by gas chromatography/mass spectrometry (GC/MS) 
[131]. To determine sarcosine in urinary samples taken from patients suffering from PCa, high 
performance liquid chromatography (HPLC) with tandem MS, which is one of the most widely used 
analytical methods, was also used [133]. However, HPLC/MS may show inconsistent results among 
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various authors, which may be due to the fact that alanine and sarcosine co-elute on an HPLC 
reversed-phase column and the mass spectrometer cannot differentiate between the two isomers 
[134]. Therefore, Meyer et al. [134] developed a reproducible and high-throughput HPLC/MS method 
to separate sarcosine from α- and β-alanine and to quantify sarcosine in human serum and urine. Wu 
et al. [135] applied isotope dilution gas chromatography/mass spectrometry (ID GC/MS) 
metabolomic approach combined with microwave-assisted derivatization (MAD) to analyze the 
urinary metabolomic information in PCa patients and participants with benign prostate hypertrophy 
and healthy persons. Biavardi et al. [136] introduced a cavitand-functionalized silicon surface as 
supramolecular receptor that was able to recognize sarcosine from its nonmethylated precursor, 
glycine, in water and urine. Bianchi et al. [137] developed a high-throughput method for the direct 
determination of sarcosine in urine and urinary sediments using hexyl chloroformate derivatization 
followed by direct immersion solid-phase micro extraction and fast gas chromatography–mass 
spectrometric analysis. Lan et al. [138] reported colorimetric determination of sarcosine in urine 
samples of prostatic carcinoma by mimic enzyme palladium NPs. We previously described an 
ultrasensitive specific biosensing system for detecting sarcosine based on Förster resonance energy 
transfer (FRET), employed for sarcosine quantification in prostatic cell lines (PC3, 22Rv1, PNT1A), 
and urinary samples of prostate adenocarcinoma patients [53]. As showed in our previous studies 
[61,132], the electrochemical detection can be considered as a convenient technique to detect sarcosine 
in very low concentration. However, this method can be used to analyze real samples only after 
application of appropriate pre-treatment [61,132]. In contrast, the method based on NPs developed 
in this study has been successfully tested on real urine specimens. In addition, it is very simple, rapid, 
sensitive, low-cost and repeatable. 
4. Materials and Methods 
4.1. Chemicals 
Low molecular weight chitosan (CS), sodium tripolyphosphate (TPP) penta basic, dimethyl 
sulfoxide (DMSO), 3,3′,5,5′-tetramethylbenzidine (TMB), sodium citrate dihydrate, hydrogen 
tetrachloroaurate (III) tetrahydrate (HAuCl4·4H2O), hydrogen peroxide (H2O2), hydroxylammonium 
chloride (NH2OH·HCl), sodium carbonate anhydrous (Na2CO3), sodium hydrogen carbonate 
(NaHCO3), disodium hydrogen phosphate dodecahydrate (Na2HPO4·12H2O), sodium 
dihydrogenphosphate dihydrate (NaH2PO4·2H2O), acetic acid (HAc), and sodium acetate (NaAc) 
were all purchased from Merck. All reagents were of analytical grade and used without any further 
purification. Ninhydrin, hydrindatin were purchased from Ingos (Prague, Czech Republic). Aqueous 
solutions for size analysis were prepared using PURELAB® Ultra (Elga, High Wycombe, United 
Kingdom) resistivity 18 MΩ-cm. For other purposes deionized water was used. 
4.2. Synthesis of SPIONs/Au/NPs 
1.3 g of Fe(NO3)3·9H2O was dissolved in 80 mL of water (18 MΩ). A quantity of 1.4 mL 25% NH3 
was diluted in 8.6 mL water and 0.2 g NaBH4 was dissolved in this mixture and, subsequently, the 
mixture was stirred (300 rpm, 10 min at 22 °C). The solution color turned to dark brown. The mixture 
was heated to 100 °C for 2 h and stirred (300 rpm, stirring overnight at room temperature). The 
magnetic particles were separated from the solution via magnet and washed several times in water. 
The solution of HAuCl4 (20 mL, 1 mM) was added to the magnetic particles and stirred (300 rpm 3 h 
at 22 °C). Subsequently, the solution of C6H5Na3O7·2H2O (0.5 mL, 0.265 g/10 mL) was added to the 
mixture and stirred overnight. Finally, the gold SPIONs were separated via magnet and dried (40 
°C). 
4.3. Modification of SPIONs/Au/NPs with Chitosan (CS) 
SPIONs/Au/NPs (40 mg) were washed 3 times with 1000 µL of 1× phosphate buffered saline 
(PBS) (pH 7.0), mixed using a vortex mixer for 60 s, and then separated using a neodymium magnet. 
Subsequently, SPION/Au/NPs were dispersed using ultrasonic (USC-T, VWR, Radnor, USA) 40 W 
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for 10 min. The prepared NPs (SPIONs/Au/NPs) were subsequently modified with 438 µL 1% acetic 
acid and a 62 µL of CS (8 mg/mL). Incubation of the NPs took place for 30 min on a rotator (Multi-RS 
60, Biosan, Riga, Latvia) (rpm 30; deg. 84°/10; vibro pause 5°/5). To create the CS polymer structure, 
500 µL TPP (0.1 mg/mL in 1% acetic acid) was added. Subsequently, NPs were incubated on a rotator 
(Multi-RS 60, Biosan, Riga, Latvia) for 30 min (rpm 30; deg. 84°/10; vibro pause 5°/5) and temperature 
of 22 °C to produce SPIONs/Au/CS/NPs. SPIONs/Au/CS/NPs (40 mg) were washed 3 times with 1000 
µL of 1% acetic acid, 120 rpm for 60 s, and then separated using a neodymium magnet and stored at 
4 °C for further use. 
4.4. Modification of SPIONs/Au/CS/NPs with Sarcosine Oxidase (SOX) 
SPIONs/Au/NPs (40 mg) were washed 3 times with 1000 µL of 1× PBS (pH 7.0), 120 rpm for 60 
s, and then separated using a neodymium magnet. Subsequently, SPIONs/Au/NPs were dispersed 
using ultrasonic (USC-T, VWR, Radnor, USA) 40 W for 10 min. The prepared NPs (SPIONs/Au/NPs) 
were then modified with 338 µL of 1% acetic acid and 62 µL of CS (8 mg/mL) and 100 µL of SOX. 
Incubation of the NPs took place for 30 min on a rotator (Multi-Rotator RS 60, Biosan, Riga, Latvia) 
(rpm 30; deg. 84°/10; vibro pause 5°/5). To form the CS polymer structure, 500 µL of TPP (0.1 mg/mL 
in 1% acetic acid) was added. Subsequently, NPs were incubated on a rotator (Multi-Rotator RS 60, 
Biosan, Riga, Latvia) for 30 min (rpm 30; deg. 84°/10; vibro pause 5°/5) and temperature of 22 °C to 
produce SPIONs/Au/CS/SOX/NPs. SPIONs/Au/CS/SOX/NPs (40 mg) were washed 3 times with 1000 
µL of 1% acetic acid, 120 rpm for 60 s, and then separated using a neodymium magnet and stored at 
4 °C for further use. 
4.5. Scanning Electron Microscopy 
Structure of NPs was characterized by scanning electron microscopy (SEM). For documentation 
of the NPs structure, the MIRA3 LMU (Tescan, Brno, Czech Republic) was used. This model is 
equipped with a high brightness Schottky field emitter for low noise imaging at fast scanning rates. 
The SEM was fitted with In-Beam SE detector. An accelerating voltage of 15 kV and beam currents 
about 1 nA gave satisfactory results regarding maximum throughput. 
4.6. Absorbance Measurements 
Absorbance scan was carried out in the range 300–850 nm by 2 nm steps. The samples for 
measurements (100 µL) were placed in 96-well UV plate (IAB, Prague, Czech Republic). All 
measurements were performed at 22 °C (V UV-3100PC, VWR, Radnor, USA). The absorbance or 
spectra in plate (Brand, Wertheim, Germany) were recorded by using a reader Infinite M200 (Tecan, 
Männedorf, Switzerland). 
4.7. Zetasizer Analysis of Nanoparticles 
The size distribution (i.e., the hydrodynamic diameter, DH) was determined by dynamic light 
scattering (DLS) using the Zetasizer Nano ZS ZEN3600 (Malvern Instruments, Malvern, UK) with the 
detection angle of 173° in optically homogeneous square polystyrene cells. The samples were diluted 
hundredfold with deionized water. All measurements were performed at 25 °C. Each value was 
obtained as an average of 5 runs with at least 10 measurements. Version 7.10 of the Zetasizer Software 
was applied for data evaluation. The particle charge (ζ-potential) was measured by the 
microelectrophoretic method using a Malvern Zetasizer Nano ZS ZEN3600 (Malvern Instruments, 
Malvern, UK). All the measurements were performed at 25 °C in polycarbonate cuvettes. Each value 
was obtained as an average of 5 subsequent runs of the instrument with at least 20 measurements. 
4.8. Ninhydrin Assay for Chitosan (CS) Detection 
The reaction solutions were then processed as described by Sabnis and Block [139] with a 
modification reported in our previous study [109]. The ninhydrin reagent was freshly prepared on 
the day of the assay by adding 25 mL of 4 M acetate buffer (pH 5.2) to 2 g ninhydrin and 0.3 g 
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hydrindantin in 75 mL DMSO. For the assay, 75 µL of reagent was added to 100 µL of the sample in 
an Eppendorf microtube. The microtubes were immediately capped, briefly shaken by hand and 
heated in a thermoblock at 99 °C for 30 min to allow the reaction to proceed. After cooling, 15 mL of 
a 1:1 ethanol: water mixture was added to each sample. The color intensity of the complex was 
spectrophotometrically evaluated as a measure of depolymerized CS activity. Accurately weighed 
depolymerized CSs were dissolved in 1% w/v acetic acid. A blank solution was also prepared in an 
identical manner, wherein 1% w/v acetic acid was used instead of a CS solution to prepare the reaction 
mixture. The effect of the solvent system was nullified by calibrating the instrument to 100% 
transmittance of the blank. Particles preparation (SPIONs/Au/CS/SOX/NPs): 25 µL of NPs and 145 
µL of ninhydrin reagent were pipetted. Then, incubation on a thermoblock (Bio-DTB-100, Biosan, 
Riga, Latvia) at 100 °C for 30 min was carried out. After incubation, the solution was pipetted into 
the plate, free of particles, which were held by the magnet. Measurement was performed by using a 
reader Infinite M200 (Tecan, Männedorf, Switzerland): 250–800 nm, at 26 °C, step 2 nm. Relative 
absorbance (RA ninhydrin factor) of each prepared SPIONs solution was calculated as follows: 
RA = absorbance of 100 µg/mL CS solution/absorbance of NPs solution (1) 
4.9. SOX Activity of SPIONs/Au/CS/SOX/NPs 
For SOX activity of SPIONs/Au/CS/SOX/NPs measurement, the concentration of SPIONs of 40 
mg/mL was used. For reaction with the sample (sarcosine), 0.2 M phosphate buffer (pH 8), 4-
aminoantipyrine (0.1–5 mM), and phenol (1–25 mM) were used. The ratio of the sample to the 
reaction solution was 1:5. Subsequently, the samples were shaken every second minute for 30 min (3 
s, 5 amplitudes). After 30 min, the particles were separated, the solution was pipetted into a new well 
of the microtiter plate. Measurement was performed at a wavelength of 500 nm at laboratory 
temperature. 
4.10. Pseudo-Peroxidase Assay 
NPs (10 µL) were pipetted into plate (Brand, Wertheim, Germany) to 200 µL of substrate 
solution. The substrate solution was composed of: 915 µL of 0.5 M acetate buffer (pH 4.0) and 100 µL 
of 5 mM TMB (100% DMSO) along with 85 µL H2O2 (30%). CS-modified SPIONs were first washed 
(3 times at 120 rpm for 10 s, and then separated using a neodymium magnet) with 200 mM phosphate 
buffer (100 µL) at pH 8. Washing the modified SPIONs was carried out in a well of the microtiter 
plate where 200 µL of 200 mM phosphate buffer (pH 8.0) was added to 10 µL of particles, then the 
particles were separated by a magnet. Subsequently, 200 µL of substrate solution with TMB was 
added to the particles which remained in the wall. After 30 min incubation, with shaking at 2 min 
intervals, the color development appeared. After another 30 min, the particles were separated and 
the reacted solution was pipetted into a new plate and measured at 650 nm. The color development 
appeared after incubation. The absorbance or spectra were recorded by using a reader Infinite M200 
(Tecan, Männedorf, Switzerland). Spectra are very well observable at 650 nm. The measurement 
parameters were: 2 nm step, temperature 25 °C, and maximum 650 nm. To evaluate the pseudo-
peroxidase activity, the absorbance value was used at 30 min. As a control sample for assessment of 
pseudo-peroxidase activity, 10 µL of 1 U horseradish peroxidase (HRP) and 200 µL of substrate 
solution was used per reaction. 
4.11. Creatinine Analysis 
Creatinine was determined using Greiner procedures on BS-200 Chemical Analyser (Mindray, 
Shenzhen, China). The method for the analysis of creatinine was evaluated at 510 nm (picrate method 
[140]). The recording of experimental data was performed as a kinetic reaction at 16 s-intervals period. 
Parameters of the test were: incubation time 1 min and reaction time 2 min. The amount of pipetted 
reagent R1 (0.16 mM sodium hydrochloride) was 180 µL, and R2 (4 mM, picric acid) 30 µL. 10 µL of 
urine (20 times diluted with distilled water) was used in the reaction. Concentrations of creatinine 
were determined according to the following equation: 
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y = 1.5266x + 3.1532, r = 0.9994 (2) 
4.12. Growth Inhibition Assay 
Saccharomyces cerevisiae (ATCC 9763), Escherichia coli and Staphylococcus aureus were obtained 
from the Czech Collection of Microorganisms, Faculty of Science, Masaryk University, Brno, Czech 
Republic. For the determination of growth curves of experimental models selected, the LB medium 
(trypton, yeast extract, NaCl) was used. The cultures were first cultivated for 24 h, then diluted to 0.1 
of the optical density (OD) at 600 nm and placed in a well for 24 h. Cultivated yeast (S. cerevisiae) and 
microorganisms (E. coli, S. aureus) were diluted using LB media to the OD of 0.1 before measurement. 
250 µL of diluted yeast or microorganisms was pipetted into each well and 50 µL of the subsequent 
tested sample was added. As a control, the 300 µL of LB media was added to the separate well. The 
measurement was carried out on the Infinite 200 PRO multifunctional microplate reader (Tecan, 
Männedorf, Switzerland) at 600 nm for 18 h and 37 °C. The absorbance value was recorded every 30 
min. Each sample was analysed using 5 independent repetitions. The results were expressed as a 
average value. After measuring the growth curves, the IC50 was calculated by probit analysis using 
the QINSLAB information system. 
4.13. Hemolytic Assay 
Hemolytic assay was done on erythrocytes. Plasma from the fresh blood sample (RBC 5.16 · 1012 
L; HBG 161 g/L; MCV 83.6 fL, hematology analyzer Mindray BC-5500, Shenzhen, China) was 
removed by multiple washings with PBS (35 mM phosphate, pH 7.0, 150 mM NaCl) and re-
suspended to 4% (v/v) in PBS. Then, 0.2 mL of washed blood and 0.8 mL of NPs (NPs were diluted 
in PBS) were mixed in an Eppendorf microtube, and the mixture was incubated for 2 h, with gentle 
stirring at half hour intervals. After incubation, the mixture was centrifugated at 2000 g for 10 min. 
Then, 100 µL of the supernatant was taken into the microtiter plate. Absorbance at 570 nm and 
absorption spectrum from 300 to 850 nm were measured. As a positive and a negative control, 0.8 mL 
of 18 MΩ water was mixed with 0.2 mL of RBC, and 0.8 mL of PBS with 0.2 mL of RBC, respectively. 
After completion of the incubation period, the cells were centrifuged, and the absorbance of the 
supernatant containing lysed erythrocytes was measured at 570 nm. The percentage of the hemolysis 
was determined by the following equation: 
% hemolysis = [(At − Ac)/(A100% − Ac)] × 100 (3) 
Where At is the absorbance of the supernatant from samples incubated with the particles, Ac is the 
absorbance of the supernatant from negative control (PBS), and A100% is the absorbance of the positive 
control supernatant. 
4.14. Biological Samples of Urine 
Urine samples obtained from healthy volunteers (K) were collected at time intervals. Samples P 
were obtained from patients-voluntary donors with a histologically confirmed diagnosis of PCa. All 
procedures were performed in accordance with ethical principles. Sarcosine content was analyzed by 
the proposed method. All participants signed informed consent to use their biological sample 
(E01/2017). From all participants, the informed consent for the collection and analysis of clinical 
samples was obtained. Sample analysis was performed by the methodology developed in this article. 
4.15. Data Treatment and Descriptive Statistics 
The experimental work was carried out in 3 independent experiments. The analysis of each 
sample was carried out 5 times. The obtained data are presented as average values. From the 
proposed study no experimental subjects were excluded from the proposed experimental studies. All 
the obtained data were stored in the QINSLAB database. If possible, data were processed and 
evaluated mathematically and statistically in the QINSLAB database. Photographs were processed 
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by programme ColorTest, which assigns intensity to the individual pixels of the studied image in the 
color area. For publication purposes, data were processed using Microsoft (Redmond, USA). 
5. Conclusions 
The role of sarcosine is substantial in both physiological and pathophysiological processes. The 
amount of sarcosine can be bioanalytically determined by liquid chromatography, but this method 
does not achieve the required sensitivity. Therefore, new ways for sarcosine determination are 
sought. In this work, we used nanoconstructs—SPIONs—to develop a biosensor for sarcosine as a 
potential biomarker for prostate cancer. To increase the sensitivity of the assay, pseudo-peroxidase 
activity of gold SPIONs was utilized. The designed detection system was tested in artificial urine 
specimens and also applied to real urine specimens. The proposed procedure enables the analysis of 
sarcosine at micromolar levels, and is very sensitive, affordable, and suitable for monitoring urine 
sarcosine concentrations in prostate cancer patients, and could also be used for screening testing. The 
proposed technology allows subsequent development in the field of designing new types of fluid 
chips or microchips for targeted personalized medicine. 
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Abbreviations 
r correlation coefficient 
LOD limit of detection determined by the ISO method 
LOQ limit of detection determined by the second ISO method 
RSD 
relative standard deviation calculated from the individual measurements and fit into the straight 
line equation and compared to the input value 
SOX sarcosine oxidase (EC 1.5.3.1) 
SPION superparamagnetic iron oxide nanoparticles 
TPP sodium tripolyphosphate 
TMB 3,3′,5,5′-tetramethylbenzidine 
CS chitosan 
4-AAP 4-aminoantipyrine 
IC50 the half maximal inhibitory concentration 
RBC red blood cell 
AuNPs gold nanoparticles 
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